B network Revenue and Competitors
Estimated Revenue & Valuation
- B network's estimated annual revenue is currently $22.8M per year.
- B network's estimated revenue per employee is $205,000
Employee Data
- B network has 111 Employees.
- B network grew their employee count by 14% last year.
B network's People
Name | Title | Email/Phone |
---|---|---|
1 | Head London Office | Reveal Email/Phone |
B network Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $22.8M | 111 | 14% | N/A | N/A |
#2 | $15.8M | 77 | 15% | N/A | N/A |
#3 | $6.4M | 39 | 50% | N/A | N/A |
#4 | $0.2M | 2 | 0% | N/A | N/A |
#5 | $16.2M | 79 | 49% | N/A | N/A |
#6 | $5.1M | 31 | 11% | N/A | N/A |
#7 | $2.1M | 17 | 6% | N/A | N/A |
#8 | $3.2M | 22 | -15% | N/A | N/A |
#9 | $9.4M | 51 | -4% | N/A | N/A |
#10 | $1.8M | 15 | N/A | N/A | N/A |
What Is B network?
bnetwork was founded in 2005 We provide an excellent accommodation experience through state-of-the-art platforms dedicated to your event Our vast experience in the events industry allows us to expect the unexpected and react accordingly. we are here to support our partners We thrive in making our customers happy
keywords:N/AN/A
Total Funding
111
Number of Employees
$22.8M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
B network News
Patients with relapsed/refractory large B-cell lymphomas experienced durable responses to treatment with lisocabtagene maraleucel.
Patients with high-risk large B-cell lymphoma experienced potent, long-term responses following treatment with axicabtagene ciloleucel in...
Boba Network Valuation Hits $1.5B After $45M Series A Round · Crypto exchanges Crypto.com, Huobi and BitMart participated in the round · Boba...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $16.1M | 111 | 5% | N/A |
#2 | $17.8M | 111 | 2% | N/A |
#3 | $28.4M | 112 | 13% | N/A |
#4 | $30.5M | 113 | 4% | N/A |
#5 | $20.3M | 113 | 5% | N/A |